Dr Landgren speaks to ecancer about the study presented at ASH 2020 regarding the evaluation of minimal residual disease (MRD) negativity in patients with relapsed or refractory multiple myeloma treated in the CANDOR study.
He says CANDOR is a multicentre, phase 3, randomised study of adult patients with relapsed or refractory multiple myeloma (RRMM) previously treated with 1-3 prior lines of therapy. He moves on to explain the methodology of the study and says that 466 patients received carfilzomib, dexamethasone, and daratumumab (KdD) or carfilzomib and dexamethasone (Kd) in 2:1 randomisation.
Dr Landgren explains that the primary endpoint, KdD demonstrated superior progression-free survival (PFS) vs Kd. He further mentions some of the key results of this study and the future impact these results can have on the treatment of multiple myeloma patients.
ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.